News | September 24, 2025
Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
CRISPR-based detection enables highly specific molecular recognition
The facility has been designed with a dual focus on efficiency and sustainability
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
Subscribe To Our Newsletter & Stay Updated
